The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.
READ SOURCE
The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.
READ SOURCE
This website uses cookies. By continuing to use this site, you accept our use of cookies.